RNA interference (RNAi) is a collection of small RNA directed mechanisms that result in sequence specific inhibition of gene expression. The notion that RNAi could lead to a new class of therapeutics caught the attention of many investigators soon after its discovery. The field of applied RNAi therapeutics has moved very quickly from lab to bedside. The RNAi approach has been widely used for drug development and several phase I and II clinical trials are under way. However, there are still some concerns and challenges to overcome for therapeutic applications. These include the potential for off-target effects, triggering innate immune responses and most importantly obtaining specific delivery into the cytoplasm of target cells.
The RNAi for Therapeutic market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.

Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status (2015-2020), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to end users of this industry are analyzed scientifically, the trends of product circulation and sales channel will be presented as well. Considering COVID-19, this report provides comprehensive and in-depth analysis on how the epidemic push this industry transformation and reform.

In COVID-19 outbreak, Chapter 2.2 of this report provides an analysis of the impact of COVID-19 on the global economy and the RNAi for Therapeutic industry.
Chapter 3.7 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 7-11 consider the impact of COVID-19 on the regional economy.

The RNAi for Therapeutic market can be split based on product types, major applications, and important countries as follows:

Key players in the global RNAi for Therapeutic market covered in Chapter 12:
Benitec Biopharma
Biogazelle
Alnylam Pharmaceuticals
Sylentis
Roche Innovation Center Copenhagen (formerly Santaris Pharma)
AstraZeneca
Silence Therapeutics
Tekmira Pharmaceuticals.
Silenseed
Astellas Pharma
GeneCopoeia
Arrowhead Research
Ascletis Pharmaceuticals
BioSpring
Bayer Heathcare
Ensysce Biosciences
Creative Animodel
CombiMatrix
Calando Pharmaceuticals
Quark Pharmaceuticals
Celgene
Celsion Corporation
Gradalis Incorporated
RXi Pharmaceuticals

In Chapter 4 and 14.1, on the basis of types, the RNAi for Therapeutic market from 2015 to 2025 is primarily split into:
siRNA
miRNA
shRNA

In Chapter 5 and 14.2, on the basis of applications, the RNAi for Therapeutic market from 2015 to 2025 covers:
Cancer
Cardiovascular
HBV
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 6, 7, 8, 9, 10, 11, 14:
North America (Covered in Chapter 7 and 14)
United States
Canada
Mexico
Europe (Covered in Chapter 8 and 14)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 9 and 14)
China
Japan
South Korea
Australia
India
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 10 and 14)
Saudi Arabia
UAE
Egypt
Nigeria
South Africa
Others
South America (Covered in Chapter 11 and 14)
Brazil
Argentina
Columbia
Chile
Others

Years considered for this report:
Historical Years: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2020-2025